Skip to main content

Table 1 Patient characteristics

From: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease

Age, median (range) 37 (21–72)
Female/Male 10/18
Montreal classification of Crohn’s disease
Location, n (%)
 L1 Ileal 9 (32)
  L2 Colonic 2 (7)
  L3 Ileocolic 17 (61)
 Behavior, n (%)
  B1 non-stricturing, non-penetrating 5 (18)
 B2 stricturing 21 (75)
  B3 penetrating 2 (7)
 Medication, n (%)
  5-ASA 21 (75)
  Azathioprine 14 (50)
  Prednisolone 4 (14)
Biologics naïve, n (%) 12 (32)
Duration of UST treatment (weeks), median (range) 48 (24–112)
Endoscopic examination (weeks), median (range) 49 (18–112)
  1. 5-ASA, 5-aminosalicylic acid; UST, ustekinumab